Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PHRRF$0.04+0.00(+2.70%)PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157[10:01:00 AM ET]SMX$1.82+0.04(+2.01%)TechCrunch Feature on SMX Latest in Media Coverage of Company's Growing Global Profile and Technology[10:00:00 AM ET]ROK$447.03+3.22(+0.73%)Rockwell Automation Introduces SecureOT Capabilities to Help OEMs Address Emerging Cybersecurity Regulations Rockwell Automation, Inc. (NYSE: ROK), the world's largest company dedicated to industrial automation and digital transformation, today announced new ...[10:00:00 AM ET]APPN$50.99-0.97(-1.87%)Appian Announces 2026 US Public Sector Partner Award Winners Appian (Nasdaq: APPN) today announced the winners of its 2026 US Public Sector Partner Awards at Appian Government. The annual awards recognize...[10:00:00 AM ET]EDGM$0.00-0.00(-33.33%)EdgeMode Answers the Call for Ready-to-Build Data Center Infrastructure to Shorten Lead Times[10:00:00 AM ET]AUXXF$0.30+0.02(+6.05%)A2GOLD TO SELL BOLO FOR $1.5 MILLION AND UP TO $2.8M IN CONTINGENT PAYMENTS A2Gold Corp. ("A2Gold" or the "Company") (TSX-V: AUAU) (OTCQX: AUXXF) (FRA: RR7) is pleased to announce that it has entered into a definitive Mining...[9:41:00 AM ET]ZENA$0.92-0.00(-0.43%)AI Transforming Land Surveying as Billions in Geospatial and Construction Markets Fuel New Growth Opportunities[9:40:00 AM ET]SGU$13.06-0.02(-0.11%)Bally's Corporation Comments on The Star Entertainment Group AUSTRAC Decision and Continued Turnaround[9:39:00 AM ET]AIDX$0.25-0.00(-1.17%)20/20 BioLabs to Host November 4 Investor Webinar on OneTest™ Commercial Expansion and Growth Strategy[9:37:50 AM ET]NVAX$10.34+0.02(+0.15%)Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe Novavax (Nasdaq: NVAX) has earned a $125 million milestone payment with the initiation (fifth patient dosed) of Sanofi's Phase 3 influenza-COVID-19...[9:37:00 AM ET]APPN$50.99-0.97(-1.87%)Appian Marks Major Milestone in Supporting US Army Ammunition Modernization Appian (NASDAQ: APPN) today announced that the US Army fielded the initial release of the Total Army Combat and Training Munitions Information System ...[9:35:00 AM ET]DTE$133.38+1.42(+1.08%)DTE Energy and sonnen Launch Michigan's First Residential Battery Virtual Power Plant Pilot to Explore New Ways to Lower Energy Costs DTE Energy and sonnen today announced the launch of Michigan's first residential battery virtual power plant (VPP) pilot at Veridian at County Farm,...[9:34:00 AM ET]MAN$45.52-0.23(-0.50%)TAPFIN Marks Five Consecutive Years of Everest Group SOW PEAK Matrix® Leadership Talent Solutions TAPFIN, part of the ManpowerGroup (NYSE: MAN) family of brands, has been named a Global Leader and Star Performer in the Everest...[9:31:00 AM ET]

CADL · NASDAQ

Candel Therapeutics, Inc.

$8.72 +0.04 (+0.46%)

Company overview

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development of immunotherapies for cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for the treatment of prostate cancer, and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics was incorporated in 2003 and is based in Needham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$667M
Employees
38
Headquarters
Needham, MA
Website
candeltx.com
CEO
Paul-Peter Tak
Listed
July 27, 2021
P/E
-8.85
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$56.4M
EBITDA
-$50.3M
Net income
-$54.4M
EPS
-$0.98
Total assets
$202M
Total debt
$1.8M
Earnings yield
-11.30%

Price chart

5.797.9210.0612.1914.32
CADL 1D NASDAQ O8.13H8.69L8.13C8.68+0.43 (+5.21%)Vol205.52K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics to Present at November Investor Conferences GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Appoints Maria Ostrovsky as General Counsel GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics to Present at the SITC 2026 Annual GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces Inducement Grants Under GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces Publication of Phase 2a Trial GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces Integrated Clinical and GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 GlobeNewsWire
CADLCandel Therapeutics, Inc. Stock news Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 Seeking Alpha
CADLCandel Therapeutics, Inc. Stock news This Macerich Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Benzinga
CADLCandel Therapeutics, Inc. Stock news 4 Prostate Cancer Drug Stocks to Watch During Awareness Month Zacks Investment Research
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics to Present at September Investor Conferences GlobeNewsWire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights GlobeNewsWire
CADLCandel Therapeutics, Inc. Stock news Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up MarketBeat
CADLCandel Therapeutics, Inc. Stock news Candel Therapeutics: Getting Closer, And Building Out More Paths Seeking Alpha
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 GlobeNewsWire
CADLCandel Therapeutics, Inc. Stock news Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential Seeking Alpha
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors GlobeNewsWire
CADLCandel Therapeutics, Inc. Press release Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer GlobeNewsWire
See more
FAQ

Questions about Candel Therapeutics, Inc.

What does Candel Therapeutics, Inc. do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development of immunotherapies for cancer patients. The company develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer, Phase III clinical trials for the treatment of prostate cancer, and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics was incorporated in 2003 and is based in Needham, Massachusetts.
What is CADL's market cap?
Candel Therapeutics, Inc. (CADL) is a listed stock with a live quote. The latest market cap on this page is $667M.
Where is Candel Therapeutics, Inc. headquartered?
Candel Therapeutics, Inc. is headquartered in Needham, MA.
How do I get CADL news from the API?
Call GET /v1/news?tickers=CADL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does CADL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CADL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the CADL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs